Storm Therapeutics Ltd has raised an additional £14 million in Series A money bringing the total for the early investment round up to £30 million. The new money includes funding from the new investor, Seroba Life Sciences, as well as from existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group
The extension will enable to the company to advance its preclinical pipeline of products that modulate RNA modifying enzymes for oncology.
Storm Therapeutics announced the new financing on 20 May 2019.